Evidence map›Paper›PMID 42712960›Full record

ArticleMolecular therapy. Nucleic acids2026

Dual recognition drives site-directed G-quadruplex stabilization: Oligonucleotide design in G4 ligand-oligonucleotide conjugates.

Alva Abrahamsson, Sakina Khwaja, Namrata Chaudhari, Steven Vertueux, Andreas Berner, Koit Aasumets, Chandan Kumar, Lotte Stietz, Tom Baladi, Anders Dahlén and 2 more

Abstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alva AbrahamssonDepartment of Chemistry, Umeå University, 901 87 Umeå, Sweden.
Sakina KhwajaDepartment of Chemistry, Umeå University, 901 87 Umeå, Sweden.
Namrata ChaudhariDepartment of Medical Biochemistry and Biophysics, Umea University, 907 36 Umeå, Sweden.
Steven VertueuxDepartment of Chemistry, Umeå University, 901 87 Umeå, Sweden.
Andreas BernerDepartment of Medical Biochemistry and Biophysics, Umea University, 907 36 Umeå, Sweden.
Koit AasumetsDepartment of Medical Biochemistry and Biophysics, Umea University, 907 36 Umeå, Sweden.
Chandan KumarChemical Biology Consortium Sweden (CBCS), Department of Chemistry, Umeå University, 901 87 Umeå, Sweden.
Lotte StietzDepartment of Chemistry, Umeå University, 901 87 Umeå, Sweden.
Tom BaladiNucleic Acid Therapeutics, Discovery Sciences, Biopharmaceuticals R&D - AstraZeneca Gothenburg, 431 83 Mölndal, Sweden.
Anders DahlénNucleic Acid Therapeutics, Discovery Sciences, Biopharmaceuticals R&D - AstraZeneca Gothenburg, 431 83 Mölndal, Sweden.
Sjoerd WanrooijDepartment of Medical Biochemistry and Biophysics, Umea University, 907 36 Umeå, Sweden.
Erik ChorellDepartment of Chemistry, Umeå University, 901 87 Umeå, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

G-quadruplex (G4) DNA structures are increasingly recognized for their roles in transcriptional regulation and genome stability, making them attractive therapeutic targets. Selective recognition of individual G4s remains challenging due to the high structural similarity among G4 motifs. G4 Ligand-Oligonucleotides conjugates (GL-Os) address this challenge by combining small-molecule G4 ligands with the sequence specificity of oligonucleotides, targeting sequences flanking the intended G4 target. Here, we systematically investigate how oligonucleotide length, backbone composition, and sequence complementarity govern GL-O binding, selectivity, and G4 stabilization. We show that effective G4 recognition depends on the interdependence between oligonucleotide hybridization and G4 ligand binding, such that both elements cooperatively reinforce complex stability and site specificity. Longer oligonucleotides promote more stable complexes and stronger G4 stabilization, whereas central mismatches disrupt this dual-recognition mechanism. Replacement of DNA with peptide nucleic acids (PNAs) enhances binding strength, thermal stability, and metabolic stability. Importantly, ligand conjugation redirects PNA oligonucleotides from nonspecific polymerase stalling toward selective G4 stabilization. Finally, we demonstrate receptor-mediated cellular uptake of modified GL-Os, supporting the feasibility of cellular delivery while highlighting remaining delivery barriers. Together, these findings show the molecular design principles governing GL-O behavior and provide a foundation for the future development and evaluation of selective G4-targeting therapeutics.

Indexed as

c-MYCG4 ligandG4-ligand-conjugated oligonucleotideGL-OG-quadruplex DNAinter-G4 selectivityMT: Oligonucleotides: Therapies and Applicationsoligonucleotide conjugatesoncogenepeptide nucleic acidPNAselective G4 targeting

Identifiers

PMID42712960
PMCPMC13551894

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.